Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SNUG01
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase Ⅰ/Ⅱa Study of SNUG01 in Adult Subjects With ALS
Details : SNUG01 is a Cell & Gene Therapy drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Amyotrophic Lateral Sclerosis.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
September 11, 2025
Lead Product(s) : SNUG01
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
SineuGene Gains FDA IND Clearance for SNUG01 TRIM72 Gene Therapy in ALS
Details : SNUG01 is a first-in-class TRIM72-targeted gene therapy, which is currently being evaluated for the treatment of amyotrophic lateral sclerosis.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
March 24, 2025
Details : SNUG01 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Amyotrophic Lateral Sclerosis.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
October 16, 2024
Reset All
